The Google Ventures-backed company could become the first to commercialise a reversible male contraceptive drug, provided the gel is successful in Phase III.
Contraline will use the money to take its topical, reversible male contraceptive to late-stage trials. Credit: NMK-Studio / Shutterstock.com.
Contraline has closed a $92.5m Series B financing round to take its topical male contraceptive to late-stage trials – potentially positioning the company with a first-to-market advantage in the male contraceptive market.
The funding, which was co-led by RA Capital Management and BVF partners, while featuring contributions from Google Ventures, Lumira Ventures and others, will help fund Contraline’s late-stage development programme for its hormonal, once-daily, topical contraceptive called NES/T Gel, which is designed to suppress sperm production while maintaining testosterone levels in the body. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
